Otsuka

CompanyUnited States

Otsuka develops one asset, in phase 2 (sibeprenlimab in focal segmental glomerulosclerosis). Mostly antibody acting on inflammation and TNFSF13; based in the United States.

1
Asset
Furthest: Phase 2; 22
Trials: 1
Signal

Pipeline

1

sibeprenlimab
Monoclonal antibody targeting and inhibiting APRIL (TNFSF13) to reduce pathogenic antibody production.
Phase 2, Antibody, Inflammation, TNFSF13, focal segmental glomerulosclerosis, minimal change disease

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms2
Trials31
Signals2
Integrity notices1
Similar companies6

Updated 9 Oct 2026 · 50 sources